Abstract | BACKGROUND:
Nitroxoline is an FDA-approved antibiotic with potential antitumor activity. Here we evaluated whether nitroxoline has antiproliferative properties on glioma cell growth in vitro and in vivo using glioma cell lines and a genetically engineered PTEN/KRAS mouse glioma model. METHODS: RESULTS:
Nitroxoline inhibited the proliferation and invasion of glioblastoma cells in a time- and dose-dependent manner in vitro. Growth inhibition was associated with cell-cycle arrest in G1/G0 phase and induction of apoptosis via caspase 3 and cleaved poly(ADP-ribose) polymerase. In vivo, nitroxoline-treated mice had no increase in tumor volume after 14 days of treatment, whereas tumor volumes doubled in control mice. Histological examination revealed 15%-20% TUNEL-positive cells in nitroxoline-treated mice, compared with ∼5% in the control group. CONCLUSION:
|
Authors | Jelena Lazovic, Lea Guo, Jonathan Nakashima, Leili Mirsadraei, William Yong, Hyun J Kim, Benjamin Ellingson, Hong Wu, Whitney B Pope |
Journal | Neuro-oncology
(Neuro Oncol)
Vol. 17
Issue 1
Pg. 53-62
(Jan 2015)
ISSN: 1523-5866 [Electronic] England |
PMID | 25074541
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Anti-Infective Agents, Urinary
- Antineoplastic Agents
- Nitroquinolines
- nitroxoline
|
Topics |
- Animals
- Anti-Infective Agents, Urinary
(pharmacology, therapeutic use)
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Apoptosis
(drug effects)
- Brain Neoplasms
(drug therapy, metabolism, physiopathology)
- Cell Cycle Checkpoints
(drug effects)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Disease Models, Animal
- Glioblastoma
(drug therapy, metabolism, physiopathology)
- Mice
- Nitroquinolines
(pharmacology, therapeutic use)
|